Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Tarsus Pharmaceuticals, Inc. (TARS : NSDQ)

• Company Description    Tarsus Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of therapeutic candidates to address ophthalmic conditions. The company's product candidate consist TP-03 which is in clinical stage. Tarsus Pharmaceuticals Inc. is based in IRVINE, Calif. Number of Employees: 87

• Price / Volume Information    Yesterday's Closing Price: $12.57 Daily Weekly Monthly 20 Day Moving Average: 77,153 shares Shares Outstanding: 26.73 (millions) Market Capitalization: $336.02 (millions) Beta: 0.69 52 Week High: $19.66 52 Week Low: $10.80 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -19.22% -21.73% 12 Week -13.61% -19.94% Year To Date -14.26% -18.15%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 15440 LAGUNA CANYON ROAD SUITE 160 - IRVINE,CA 92618 USA ph: 949-409-9820 fax: - ir@tarsusrx.com http://www.tarsusrx.com

• General Corporate Information    Officers Bobak Azamian - President; Chief Executive Officer and Chairman Leonard M. Greenstein - Chief Financial Officer Scott Morrison - Director Bhaskar Chaudhuri - Director Rosemary Crane - Director Peer Information Tarsus Pharmaceuticals, Inc. (CORR.) Tarsus Pharmaceuticals, Inc. (RSPI) Tarsus Pharmaceuticals, Inc. (CGXP) Tarsus Pharmaceuticals, Inc. (BGEN) Tarsus Pharmaceuticals, Inc. (GTBP) Tarsus Pharmaceuticals, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 87650L103 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 12/01/22 Next Expected EPS Date: 05/09/23 Share - Related Items Shares Outstanding: 26.73 Most Recent Split Date: (:1) Beta: 0.69 Market Capitalization: $336.02 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.94 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-4.82 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 05/09/23

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.74 Price/Cash Flow: - Price / Sales: 19.32 EPS Growth vs. Year Ago Period: 31.94% vs. Previous Quarter: 41.67% Sales Growth vs. Year Ago Period: 2,858.58% vs. Previous Quarter: -% ROE 03/31/23 - -32.41 12/31/22 - -34.24 09/30/22 - -31.56 ROA 03/31/23 - -27.64 12/31/22 - -29.82 09/30/22 - -28.14 Current Ratio 03/31/23 - 14.61 12/31/22 - 16.40 09/30/22 - 21.36 Quick Ratio 03/31/23 - 14.61 12/31/22 - 16.40 09/30/22 - 21.36 Operating Margin 03/31/23 - - 12/31/22 - - 09/30/22 - -324.99 Net Margin 03/31/23 - - 12/31/22 - - 09/30/22 - -324.99 Pre-Tax Margin 03/31/23 - -240.53 12/31/22 - -351.71 09/30/22 - -326.64 Book Value 03/31/23 - 7.23 12/31/22 - 7.60 09/30/22 - 10.69 Inventory Turnover 03/31/23 - - 12/31/22 - - 09/30/22 - - Debt-to-Equity 03/31/23 - 0.10 12/31/22 - 0.10 09/30/22 - 0.09 Debt-to-Capital 03/31/23 - 9.15 12/31/22 - 8.72 09/30/22 - 8.00

Powered by Zacks Investment Research ©